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The expectation that cell-mediated immunity is important in the control of feline leukemia virus (FeLV)
infection led us to test a DNA vaccine administered alone or with cytokines that favored the development of a
Th1 immune response. The vaccine consisted of two plasmids, one expressing the gag/pol genes and the other
expressing the env gene of FeLV-A/Glasgow-1. The genetic adjuvants were plasmids encoding the feline
cytokines interleukin-12 (IL-12), IL-18, or gamma interferon (IFN-g). Kittens were immunized by three
intramuscular inoculations of the FeLV DNA vaccine alone or in combination with plasmids expressing IFN-g,
IL-12, or both IL-12 and IL-18. Control kittens were inoculated with empty plasmid. Following immunization,
anti-FeLV antibodies were not detected in any kitten. Three weeks after the final immunization, the kittens
were challenged by the intraperitoneal inoculation of FeLV-A/Glasgow-1 and were then monitored for a further
15 weeks for the presence of virus in plasma and, at the end of the trial, for latent virus in bone marrow. The
vaccine consisting of FeLV DNA with the IL-12 and IL-18 genes conferred significant immunity, protecting
completely against transient and persistent viremia, and in five of six kittens protecting against latent
infection. None of the other vaccines provided significant protection.
The retrovirus, feline leukemia virus (FeLV), is a significant
pathogen of domestic cats throughout the world, such that
there is a demand for methods to protect against the infection.
Cats exposed to FeLV may either become persistently viremic
or recover from infection. Viremic cats are anergic to FeLV
proteins, showing little evidence of an immune response to the
virus, and are at very high risk of developing a fatal disease
within 2 to 4 years. In contrast, recovered cats produce virus
neutralizing antibodies (20) and FeLV-specific cytotoxic T cells
(CTLs) (14), are resistant to reinfection, and do not develop
FeLV-related diseases (20). A third possible outcome is the
establishment of a “latent” infection, in which cats are not
viremic but have a covert infection of bone marrow cells and,
like fully recovered cats, have virus-neutralizing antibodies
(43). In most cats with latent infections the virus is eventually
eliminated, but occasionally the infection persists for several
years (53) and may be reactivated at a later date so that cats
become viremic.
The observation that cats can recover naturally from expo-
sure to FeLV led to the development of vaccines designed to
protect against FeLV infection and disease. Several FeLV vac-
cines are commercially available. These contain inactivated
virions (22, 61, 77), subunits of virions (41), or a recombinant
Env protein (8, 33, 45). The ideal vaccine should protect
against the establishment of both viremia and latent infection.
In practice, however, although the efficacy of these FeLV vac-
cines has been demonstrated (24, 41, 45, 55–57, 77), the level
of protection has not always been complete (31, 38, 39, 58).
Attempts have been made to produce more effective vaccines,
using novel adjuvants such as immune-stimulating complexes
(51, 52) or live virus vectors, including vaccinia virus, canary-
pox virus, and feline herpesvirus, that contain one or more
FeLV genes. The immune stimulating complex vaccine con-
ferred excellent protection from persistent viremia but has not
been developed for commercial use. Of the live recombinant
vaccines, the vaccinia virus was ineffective (16), while the ca-
narypoxvirus (67) and herpesvirus vaccines (73, 76) provided a
level of protection from viremia that was no better than that
produced by existing vaccines. At present, therefore, no exper-
imental or commercially available FeLV vaccine consistently
provides total protection against the development of transient
or persistent viremia or latent bone marrow infection, follow-
ing exposure to virus (65).
Naked DNA vaccination provides a new approach to the
development of stable and affordable vaccines. Experimental
DNA vaccines against viral, bacterial, and parasitic diseases
have been described (12), and their utility in the prophylaxis of
retroviral infections, such as with human immunodeficiency
virus, simian immunodeficiency virus, and feline immunodefi-
ciency virus (FIV), has been explored, with promising results
(3, 15, 25, 70, 72). In several studies, the coinoculation of
plasmids encoding cytokine genes as adjuvants significantly
enhanced the immune response raised to DNA vaccines (9),
modulating both the amplitude and the nature of the response
(7, 34, 35, 69). Although the details of the immune response
that leads to recovery from FeLV infection are not yet known,
it seemed reasonable to suppose that killing of virus-infected
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cells by CTL activity is a key element in immunity. Therefore,
this approach seemed an attractive proposition for FeLV since
DNA vaccination leads to antigen presentation through the
endogenous pathway, and genetic adjuvants can be used to
promote cell-mediated immunity. In this study we investigated
the ability of a DNA vaccine capable of expressing defective
FeLV particles to induce protection in cats against challenge
with live virus. The vaccine was evaluated either alone or in
combination with the genes of cytokines that might be ex-
pected to promote a Th1 immune response.
MATERIALS AND METHODS
Cell lines and virus strains. Cell culture media and supplements were ob-
tained from Gibco/Life Technologies, Inc., Paisley, United Kingdom. The
QN10S feline cell line was used for FeLV detection and assays of FeLV infec-
tivity and virus-neutralizing antibodies (59). The 293 cell line, human embryonic
kidney cells transformed by sheared human adenovirus type 5 DNA (18), the
derivative 293T cell line expressing the simian virus 40 (SV40) T antigen (44),
and the FEA cell line of feline embryonic fibroblasts (28) were maintained as
described previously. Primary feline alveolar macrophage cultures were estab-
lished from freshly isolated lung tissue. The macrophages were cultured in
Dulbecco modified Eagle medium (Gibco-BRL) containing 20 mM HEPES, 2
mM glutamine, 100 U of penicillin per ml, 100 mg of streptomycin per ml, and
10% fetal calf serum (Gibco-BRL) at 37°C with 5% CO2.
The FeLV challenge virus was derived from a molecular clone of FeLV-A/
Glasgow-1 (66) and was grown in FEA cells. The batch used had a titer of 2.2 3
106 focus-forming units (FFU)/ml.
Preparation of FeLV antigen DNA constructs. The FeLV DNA vaccine con-
sisted of two separate pUSE12 series constructs, one expressing FeLV gag/pol
genes and the other expressing the FeLV subgroup A env gene. The pUSE12
plasmid is a mammalian expression vector derived from the vector pCI-neo
(Promega). The cytomegalovirus (CMV) promoter was cloned into the AscI site
in pUSE12 to create pUSE12CMVT. The gag/pol genes from the FeLV A/Glas-
gow-1 molecular clone (66) were then subcloned from the vector pCDNA3
(Invitrogen B.V., De Schelp, The Netherlands) into pUSE12CMVT as a NotI
fragment to create pUSE12CMVT(gagpol), as illustrated in Fig. 1A. To create
the pUSE12CMVT(envA) construct, the env gene from the FeLV A/Glasgow-1
molecular clone was subcloned from pCDNA3 into pUSE12CMVT. The env
gene was first excised from pCDNA3 by PstI/BamHI digestion and then blunt
ended. pUSE12CMVT(gagpol) was digested with NotI, gel purified, and blunt
ended to create pUSE12CMVT. Finally, env was blunt end ligated into
pUSE12CMVT to create pUSE12CMVT(envA), as illustrated in Fig. 1B. The
plasmid pCI-neo (Promega) was used as control DNA.
In vitro expression of FeLV DNA constructs. Confirmation that the FeLV
DNA constructs pUSE12CMVT(gagpol) and pUSE12CMVT(envA) were ex-
pressed was demonstrated by fixed and live cell immunofluorescence. Duplicate
cultures of 293T cells were transfected with pUSE12CMVT(gagpol) or
pUSE12CMVT(envA) by using calcium phosphate transfection (75). After 48 h
transfected cells and nontransfected negative control cells were harvested, and
4 3 105 cells per well were coated onto multispot slides. After an overnight
incubation at 37°C, cells transfected with pUSE12CMVT(gagpol) were fixed
with ice-cold methanol, following two washes with phosphate-buffered saline
(PBS). Cells were then incubated for 90 min at 37°C with a gp70-specific
monoclonal antibody (MAb 6-15; a gift of Kees Weijer, Netherlands Cancer
Institute) [controls and cells transfected with the pUSE12CMVT(envA) con-
struct] or a p27-specific MAb (PF12J-10A; a gift of Chris Grant, Custom
Monoclonals, Sacramento, Calif.) [controls and fixed cells transfected with
the pUSE12CMVT(gagpol) construct]. After three PBS washes the cells were
incubated with 25 ml of anti-mouse immunoglobulin G antibody conjugated
to fluorescein isothiocyanate, diluted in RPMI medium (Gibco), for 1 h at
37°C. After three PBS washes, coverslips were placed on the slides, and the
cells were examined on a microscope with UV light. Fixed or live FeLV-
infected FEA cells, labeled with the anti-p27 and anti-gp70 MAbs, respec-
tively, served as positive controls.
In addition, the production of empty virions by 293 cells cotransfected with the
FeLV constructs and a packageable lacZ reporter gene was demonstrated. Three
plasmids were used for this purpose: pUSE12CMVT(gagpol) and pUSE12CMVT
(envA), as described above, and pHIT111. pHIT111 comprised a recombinant
Moloney murine leukemia virus vector genome, containing the lacZ gene driven
by the CMV promoter (64). 293 cells were seeded in 25-cm2 flasks and were
incubated overnight to provide cultures that were approximately 30% confluent
for transfection. Then, 5 mg of each of the three plasmids was cotransfected into
the 293 cells by using calcium phosphate transfection (75), according to the
manufacturer’s protocol (ProFection Mammalian Transfection System; Pro-
mega). After 16 h, the culture fluid was replaced with 5 ml of fresh medium, and
2 days after transfection the culture supernatants were harvested and passed
through a 0.45-mm (pore-size) syringe filter. Polybrene was added to the filtrate
to a final concentration of 8 mg/ml, and 1 ml was added to duplicate 25-cm2 flasks
of FEA cells. After 2 h the inoculum was replaced with fresh medium. Three days
after infection the cells were labeled for lacZ expression by using the b-galac-
tosidase assay method. The number of blue cells in each flask was counted to
determine if recombinant retrovirus, containing the reporter gene lacZ (express-
ing the enzyme b-galactosidase), had been produced as a result of in vitro
expression of the FeLV DNA constructs.
Preparation of cytokine adjuvant DNA constructs. The cloning and charac-
terization of the feline gamma interferon (IFN-g) gene have been described
previously (1, 2). For use as an adjuvant gene, the IFN-g cDNA was subcloned
into the pCI-neo vector (Promega) as an EcoRI-NotI fragment. Feline interleu-
kin-12 (IL-12) and IL-18 genes were isolated utilizing RT-PCR of mRNA from
feline alveolar macrophages stimulated with LPS (19). The isolation and char-
acterization of the full-length feline IL-18 gene have been described (19), and the
DNA sequence has been submitted to EMBL under accession number Y13923.
FIG. 1. (A) pUSE12CMVT(gagpol) DNA construct. (B) pUSE12CMVT(envA) DNA construct. p, 59 donor site from the first intron of the
human beta-globin gene and the branch and 39-acceptor of an immunoglobulin gene heavy-chain variable region. AMP, ampicillin resistance gene.
The pUSE12 plasmid is a mammalian expression vector derived from the vector pCI-neo (Promega).
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For use as an adjuvant gene, the IL-18 cDNA, in the mature form lacking the
inactive precursor sequence, was subcloned into the PsecI vector as an EcoRV-
NotI fragment. The PsecI vector, derived from the pCI-neo (Promega) and
pSecTag plasmids (Invitrogen), contained a synthetic immunoglobulin secretory
component to facilitate the secretion of the active form of IL-18.
The cloning and sequencing of the p35 and p40 subunits of feline IL-12 have
been described (19). To create the adjuvant constructs employed in this study,
the IL-12 p40 and p35 cDNAs were subcloned into the pCI-neo vector (Pro-
mega) as EcoRI and XhoI-NotI fragments, respectively.
In vitro expression of cytokine DNA constructs. Expression of feline IL-18 and
the p35 and p40 subunits of IL-12 in vitro was assessed using Northern blot
analysis of mRNA isolated from transfected 293T cells. To detect the expression
of the full-length IL-18 protein, lysates of cells transfected with IL-18 DNA were
also analyzed by Western blotting (68) by using a cross-reacting rabbit polyclonal
antibody against equine IL-18. Feline IL-12 protein expression was similarly
confirmed by Western blot using a rabbit polyclonal antibody raised against a
synthetic peptide homologous to feline IL-12 p40; both denaturing and nonde-
naturing conditions were used. There is currently no antibody available specific
for either feline IL-12 p35 or p70 (IL-12 heterodimer).
DNA immunization, virus challenge, and blood sampling protocol. The plas-
mid DNAs were purified by using Endofree Plasmid Giga kits (Qiagen) accord-
ing to the manufacturer’s protocol. Endotoxin levels were quantified by Q1
Biotech, Glasgow, United Kingdom, using the Limulus amebocyte lysate tech-
nique and were determined to be less than 0.5 endotoxin units/ml.
Twenty-nine specific-pathogen-free kittens, aged between 13 and 15 weeks old,
were obtained from a commercial source. They were arranged randomly into five
groups, each with six kittens, except for group B, which contained five kittens.
Each group was split between two rooms, each with 9.36 m2 of floor space and
a height of 2.36 m. The kittens were fed proprietary wet and dry cat food and also
water. The experiment was conducted in accordance with the guidelines of the
UK Home Office Inspectorate.
The kittens were immunized by the inoculation of 100 mg of each DNA
construct, in a volume of 200 ml of endotoxin-free PBS (BioWhittaker), into one
site in the quadriceps femoris muscle. Cats were immunized with the FeLV DNA
constructs alone (group A) or with these constructs and plasmids expressing
IFN-g (group B), IL-12 (group C), or both IL-12 and IL-18 (group D). Control
cats (group E) were immunized with empty plasmid (pCI-neo; Promega). Inoc-
ulations were performed on three occasions, at 7, 5, and 3 weeks before challenge
with virus. As a challenge, a dose of 2 3 105 FFU of FeLV-A/Glasgow-1 was
administered in 1 ml of endotoxin-free PBS (BioWhittaker) by intraperitoneal
inoculation.
Blood samples were collected by jugular venipuncture before the start of the
trial, 48 h after each immunization, on the day of challenge, and at intervals of
approximately 3 weeks after challenge. The samples were collected in heparin
tubes, and the plasma was separated and stored in aliquots at 270°C. The trial
was terminated 15 weeks after challenge, when blood and bone marrow samples
were collected and tested for the presence of active and, in the case of the
marrow, latent FeLV infection.
Detection of infectious FeLV. Plasma samples were tested for the presence of
FeLV by infection of QN10S cells, as described elsewhere (31). Bone marrow
samples were collected from all cats at the end of the trial, and the cells were
cultured for 14 to 17 days, as described previously (43). When the primary
cultures became confluent after 14 days, the cells were subcultured 1:2. At 7, 14,
and 17 days of culture, the culture fluids were examined for infectious virus using
QN10S cells to identify latent FeLV infection that was reactivated in vitro.
Detection of anti-FeLV antibodies. Plasma samples were tested for virus-
neutralizing antibodies to FeLV-A/Glasgow-1 using a focus reduction assay (31).
Plasma samples taken on the day of challenge were also analyzed by two other
methods for the presence of anti-FeLV antibodies induced by vaccination. An
enzyme-linked immunosorbent assay (ELISA) (74) was used to detect anti-FeLV
gp70 antibodies, and Western blot analysis (13, 26) against a lysate of purified
FeLV-A virions was performed to detect antibodies to any FeLV protein.
Statistical analyses. Statistical analysis was performed on the virus isolation
results. Measurements were taken from each of the five treatment groups (A to
E) at the four time points after challenge. Fisher’s exact test was performed for
each time point on the 2 3 5 contingency tables, constructed to illustrate the
number of positive and negative virus isolation results in each group. When a
significant overall test was detected for the data at a particular time point,
pairwise Fisher’s exact tests were performed between all pairs of treatments.
Feline IL-18 gene accession number. The feline IL-18 DNA sequence has been
submitted to the Nucleotide Sequence Database, EMBL, Outstation EBI, Cam-
bridge, England, and has been referenced under accession number Y13923.
RESULTS
FeLV DNA constructs express viral proteins that are assem-
bled to produce virions in vitro. The expression of pUSE12
CMVT(gagpol) and pUSE12CMVT(envA) constructs in trans-
fected 293T cells was demonstrated by using fixed- and live-cell
immunofluorescence. Fixed-cell immunofluorescence, utilizing
an anti-p27 MAb, demonstrated a diffuse expression pattern of
FeLV p27 protein in the cytoplasm of 293T cells transfected
with pUSE12CMVT(gagpol) (Fig. 2). Live-cell immunofluo-
rescence, utilizing an anti-gp70 MAb, demonstrated the ex-
pression of FeLV gp70 protein on the surface of 293T cells
transfected with pUSE12CMVT(envA) (Fig. 2). Expression of
these proteins was not detected in untransfected control cells
(Fig. 3). Fixed and live FeLV-infected FEA cells labeled with
anti-p27 and anti-gp70 MAbs, respectively, acted as positive
controls (Fig. 4).
FIG. 2. Photographs of fixed 293T cells transfected with
pUSE12CMVT (gagpol) DNA construct and labeled with anti-p27
MAb PF12J-10A (top) and live 293T cells transfected with the
pUSE12CMVT(envA) DNA construct and labeled with anti-gp70
MAb 6–15 (bottom). Magnification, 3200.
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The capacity of the FeLV DNA constructs to drive the
production and release of virus-like particles was also deter-
mined. The constructs were transfected together with a lacZ
reporter gene construct into 293 cells, and the culture fluid
from the transfected cells was subsequently inoculated onto
FEA cells, which are highly susceptible to FeLV. After 3 days
of incubation, the FEA cells were labeled for lacZ expression.
Approximately 0.1% of the cells in each of two flasks were
found by the b-galactosidase assay method to have stained
blue, compared to none in the control flasks. These data con-
firmed that the transfected FeLV DNA constructs were able to
produce particles in vitro that could infect cat cells.
Cytokine DNA constructs are expressed in vitro in mamma-
lian cells. It was not possible to ensure that all the cytokine
genes used in the study were expressed in a biologically active
form in cat cells. This has been achieved for the IFN-g that was
used (1), but assays of biological activity are not yet available
for feline IL-12 or IL-18. However, it was possible to demon-
strate expression of the products of the IL-12 and IL-18 genes
after transfection of the constructs into 293T cells. Northern
blot analysis to assess in vitro mRNA expression of the feline
IL-18, p35, and p40 IL-12 constructs revealed the presence of
bands at approximately 1.2, 1.5, and 1.9 kb, respectively, that
corresponded to the expected sizes of the pCI-neo derived
IL-18, p35, and p40 IL-12 mRNA transcripts (L. Hanlon, C.
McGillivray, L. Nicolson, D. E. Onions, D. J. Argyle, and S.
Dunham, unpublished data). In addition, Western blot analysis
to detect in vitro IL-18 protein expression, using a cross-reac-
tive anti-equine IL-18 polyclonal antibody, demonstrated the
presence of a single 24-kDa species, the predicted size of the
feline pro-IL-18 protein (Hanlon et al., unpublished) Similarly,
in using a rabbit anti-peptide antibody specific for feline p40, a
single 40-kDa protein was demonstrated by Western blotting in
both IL-12 p40 transfected cell supernatants and lysates. After
nondenaturing polyacrylamide gel electrophoresis, it was pos-
sible to detect a band corresponding to the predicted size of
the IL-12 p70 heterodimer in supernatants from cells trans-
FIG. 4. Photographs of fixed FeLV-A-infected FEA cells labeled
with anti-p27 MAb PF12J-10A (top) and live FeLV-A-infected FEA
cells labeled with anti-gp70 MAb 6–15 (bottom). Magnification, 3200.
FIG. 3. Photographs of untransfected fixed 293T cells labeled with
an anti-p27 MAb (PF12J-10A) (top), and untransfected live 293T cells
labeled with an anti-gp70 MAb (6–15) (bottom). Magnification, 3200.
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fected with both p40 and p35 DNA but not in supernatants
from cells transfected with either subunit alone (S. Dunham, L.
Hanlon, J. Bruce, and J. Neil, unpublished data). Taken to-
gether, these data confirmed that IL-12 and IL-18 DNA con-
structs were expressed in mammalian cells in vitro.
Infectious virus is not produced in cats as a result of ho-
mologous recombination between FeLV vaccine DNA and en-
dogenous retroviral sequences. In the vaccine trial, kittens
were inoculated with FeLV DNA and cytokine DNA on three
occasions, with an interval of 2 weeks between the inocula-
tions. Three weeks following the administration of the final
dose of vaccine the kittens were challenged by the intraperi-
toneal inoculation of FeLV. The safety of DNA vaccines is a
concern, both in terms of immediate adverse reactions and of
the longer-term consequences arising from the expression of
transfected DNA in vivo. Although the FeLV vaccine con-
structs were expressed and assembled into FeLV virions, these
empty particles lacked a functional viral genome and, conse-
quently, should not be capable of replication, proviral integra-
tion, or establishing productive infection. However, there is a
theoretical risk that the FeLV DNA constructs might be able
to recombine in vivo with endogenous feline retroviral se-
quences (49), resulting in the production of replication-com-
petent virions capable of establishing productive FeLV infec-
tion in cats.
To investigate the appearance of such recombinant viruses,
the pretrial, postimmunization, and day-of-challenge plasma
samples were tested for infectious virus. Virus was not isolated
from any blood sample collected before challenge (Table 1).
This result indicated that a recombination event between vac-
cine DNA and endogenous retroviral sequences, generating
replication-competent virus, was unlikely to have occurred in
these cats. Moreover, no local or systemic reactions were ob-
served in any kitten after immunization. Therefore, it was
concluded that the FeLV DNA vaccine and cytokine con-
structs were safe to administer to cats.
DNA immunization does not elicit antiviral antibodies. The
capacity of the vaccines to induce FeLV-specific antibodies was
determined. Antibodies were not detected by virus neutraliza-
tion (Table 1), anti-gp70 ELISA or Western blotting in the
plasma samples taken from the kittens on the day of challenge.
These results illustrated that immunization in this way did not
initiate an FeLV-specific antibody response. Further, the lack
of an antibody response is consistent with the conclusion that
TABLE 1. Results of virus isolation and virus-neutralizing antibody assay on day of challenge and at intervals following challenge
DNA
inoculum
groupa
Catalog no.
Outcome of FeLV challenge of vaccinated cats atb:
Wk 0 Wk 3 Wk 6 Wk 9 Wk 13 Wk 15
VI VN VI VN VI VN VI VN VI VN VI VIBM
Group A L1 2 0 1 0 1 0 1 0 1 0 1 1
L2 2 0 2 0 2 0 1 0 1 0 1 1
L3 2 0 1 0 2 0 2 32 2 128 2 1
L4 2 0 2 0 2 0 2 16 2 128 2 1
L5 2 0 2 0 2 0 2 16 2 32 2 2
L6 2 0 2 8 2 64 2 64 2 1,024 2 2
Group B L8 2 0 1 0 1 0 1 0 1 0 1 1
L9 2 0 1 0 1 0 1 0 1 0 1 1
L10 2 0 2 0 2 0 2 0 2 0 2 2
L11 2 0 2 0 2 0 2 0 2 0 2 2
L12 2 0 2 0 2 0 2 0 2 16 2 2
Group C L13 2 0 1 0 1 0 1 0 1 0 1 1
L14 2 0 1 0 1 0 1 0 1 0 1 1
L15 2 0 1 0 1 0 1 0 1 0 1 1
L16 2 0 1 0 1 0 2 0 2 0 1 1
L17 2 0 2 0 2 16 2 64 2 512 2 2
L18 2 0 2 0 2 8 2 64 2 1,024 2 2
Group D L19 2 0 2 0 2 8 2 32 2 64 2 2
L20 2 0 2 0 2 0 2 8 2 32 2 2
L21 2 0 2 0 2 0 2 16 2 64 2 1
L22 2 0 2 0 2 0 2 16 2 64 2 2
L23 2 0 2 0 2 0 2 32 2 128 2 2
L24 2 0 2 16 2 16 2 64 2 1,024 2 2
Group E L25 2 0 1 0 1 0 1 0 1 0 1 1
L26 2 0 1 0 1 0 1 0 1 0 1 1
L27 2 0 1 0 1 0 1 0 1 0 1 1
L28 2 0 1 0 2 0 2 8 2 128 2 1
L29 2 0 1 0 2 16 2 64 2 512 2 1
L30 2 0 2 0 2 0 2 32 2 128 2 2
a Group A, FeLV env 1 gag/pol; group B, FeLV env 1gag/pol 1 IFN-g; group C, FeLV env 1 gag/pol 1 IL-12; group D, FeLV env 1 gag/pol 1 IL-12 1 IL-18; group
E, pCI-neo plasmid.
b VI, virus isolation on plasma; VN, virus-neutralizing antibody assay; VIBM, virus isolation performed on cultured bone marrow supernatants. Values are expressed
as titers for the virus-neutralizing antibody assay.
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no replication-competent FeLV was generated during immu-
nization.
The FeLV DNA vaccine alone does not provide significant
protection against challenge with infectious virus. The efficacy
of the vaccines was assessed by their capacity to prevent the
development of transient, persistent, or latent infection after
challenge in comparison with the response of unvaccinated
control cats. Cats were monitored at 3, 6, 9, 13, and 15 weeks
following challenge for the presence of infectious FeLV in
plasma. Sampling 3 weeks after challenge can be particularly
revealing, since it is at this time that a transient viremia is most
likely to be found in cats that eventually recover from infection
(32). Protection against a transient infection would indicate
that vaccination had led to a reduction in viral growth very
early after infection. Persistent viremia was defined as the
presence of virus in the plasma at the end of the trial, i.e., 15
weeks after challenge. Virus-neutralizing antibody titers were
determined at each time point, since a significant postchal-
lenge antibody titer usually correlates with protection (23).
Virus isolation was also performed on cultured bone marrow
samples, collected 15 weeks postchallenge, when the trial
ended. The latter procedure was carried out to find if ostensi-
bly immune, nonviremic cats harbored latent FeLV infection
in bone marrow.
The results are shown in Table 1 and are summarized in
Table 2. Virus was isolated from five of the six unvaccinated,
control cats in group E at 3 weeks after challenge. For the
remainder of the trial, only three of these cats remained vire-
mic. However, virus was isolated from bone marrow cell cul-
tures from all five cats at 15 weeks after challenge. In contrast,
only two of the six cats in group A, inoculated with the FeLV
DNA vaccine alone, were viremic 3 weeks after challenge. One
of these two cats became persistently viremic, while the second
appeared to recover. A third cat (L2) became persistently
infected from 9 weeks after infection. At 15 weeks, virus was
isolated from the bone marrow of these three cats and from a
fourth cat. These results indicate that the vaccine might have
provided a degree of protection from transient viremia at 3
weeks after challenge, although the difference in the propor-
tion of viremic cats was not statistically significant between the
groups. Later, at 15 weeks after challenge, the proportion of
viremic cats in both groups A and E was almost identical.
These results, however, did not necessarily reflect a reduction
in the protective effect of the vaccine as the trial progressed but
rather that some of the infected cats in the control group (E)
cleared the virus and became nonviremic. From the results at
the end of the trial, it was concluded that the FeLV DNA
vaccine alone did not provide significant protection against
persistent viremia or latent FeLV infection, although it may
have reduced the number of transiently infected cats.
A combination of IL-12 and IL-18 cytokine DNA constructs
act as vaccine adjuvants enhancing protection against persis-
tent and latent FeLV infection. To assess the ability of cytokine
DNA constructs to enhance any immunity induced by the
FeLV DNA vaccine alone, cats in the three other groups were
coinoculated with plasmids encoding IFN-g (group B), IL-12
(group C), or a combination of IL-12 and IL-18 (group D) and
were challenged with FeLV.
Three of the five cats of group B, inoculated with the vaccine
and IFN-g DNA constructs, were consistently free from vire-
mia throughout the trial. However, statistical analysis revealed
no significant difference between the proportions of viremic
cats in this group (B), the FeLV DNA-alone group (A), or the
control group (E). Therefore, it was concluded that the FeLV
DNA vaccine and IFN-g constructs did not protect cats from
the development of transient or persistent viremia and that
IFN-g was not an effective vaccine adjuvant in this system.
Three of the six cats inoculated with the vaccine and IL-12
DNA constructs (group C) were consistently viremic from 3
weeks after challenge. A fourth cat that was viremic at 3 and 6
weeks and then appeared to recover became viremic again on
week 15 and was considered to be persistently viremic.
Throughout the trial, the proportion of viremic cats in group C
was similar to that of group E (the control group) and, remark-
ably, was consistently higher than that of group A (the FeLV
DNA vaccine alone group), although the differences were not
statistically significant. These results indicated that the FeLV
DNA vaccine and IL-12 constructs did not protect cats from
the development of transient and persistent viremia; that IL-12
was not an effective vaccine adjuvant in this system, and that
the inclusion of IL-12 DNA constructs with the FeLV DNA
vaccine might actually have reduced vaccine efficacy.
The best protection was achieved by immunization with
FeLV DNA and the combination of IL-12 and IL-18 genes
DNA (group D). None of the vaccinated cats was viremic at
any point during the trial. Compared with control group E, the
proportion of viremic cats was significantly lower in group D, at
3 weeks post-challenge (P , 0.5). However, the difference was
not significant at 15 weeks because three of the control cats
had recovered. At that time, however, two additional control
cats had a latent bone marrow infection compared to only one
of the six vaccinated cats. In addition, the virus load in the bone
marrow of the vaccinated cat must have been extremely low,
since virus was found only at the last sampling, 17 days after
TABLE 2. Summary of the number of cats with transient viremia, persistent viremia, and latent infection following challenge
Group DNA inoculum Gene adjuvant
No. of animals with: No. of animals with
persistent and latent
infections/total no.
Transient
viremiaa/total no.
Persistent
viremia/total no.
Additional latent
infection/total no.
A FeLV env 1 gag/pol None 1/6 2/6 2/6 4/6
B FeLV env 1 gag/pol IFN-g 0/5 2/5 0/5 2/5
C FeLV env 1 gag/pol IL-12 0/6 4/6 0/6 4/6
D FeLV env 1 gag/pol IL-12 1 IL-18 0/6 0/6 1/6 1/6
E pCI-neo plasmid None 2/6 3/6 2/6 5/6
a Transient viremia defined as viremia at 3 weeks postchallenge that is cleared by 6 weeks postchallenge.
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establishment of the cultures. (In comparison, virus was de-
tected within 14 days in all cultures from the control cats.) This
low level of infection was confirmed when cultures from a
second bone marrow biopsy, collected from the latently in-
fected cat in group D 7 weeks later, failed to yield virus.
Therefore, as shown in Table 2, the combined total of cats
persistently and latently infected in group D was much lower
than in either group E (controls) or group A (vaccine alone).
Hence, the combination of IL-12 and IL-18 DNA constructs
acted as a potent vaccine adjuvant, producing significant pro-
tection against FeLV challenge.
DISCUSSION
We describe here the construction of a FeLV DNA vaccine
that, when administered to cats together with a combination of
feline IL-12 and IL-18 genes, provided a high level of protec-
tion from challenge with virus. This protection was achieved
without the induction of a detectable anti-FeLV antibody re-
sponse. Based on the proportion of cats that was viremic at the
end of the trial, the differences between the group given this
vaccine and the control group were not statistically significant,
due mainly to the fact that half of the control cats recovered
naturally from the challenge. It had been expected that all of
the control cats would become persistently infected following
the intraperitoneal challenge. The recovery from viremia may
have been due to the innate resistance of 20-week-old cats
(23). Indeed it was in an attempt to overcome this potential
resistance that the intraperitoneal method of administration of
the challenge was used (45). Another possible explanation is
that the inoculation of “empty” plasmid DNA induced a non-
specific immune enhancement in the control cats. However,
overall, when the lack of transient and persistent viremia in all
cats and of latent infection in all but one cat is considered, the
level of protection conferred by the FeLV DNA together with
IL-12 and IL-18 DNA was impressive.
Since the crucial immunogens for establishing protective
immunity against FeLV are not yet known, we elected to de-
velop a vaccine that should express all of the viral genes. As
anticipated, cotransfection of cells with the plasmids contain-
ing either gag/pol or env led to the expression of viral proteins
that underwent processing and were assembled into virus-like
particles capable of infecting feline cells. Such authentic pro-
cessing might be expected to promote efficient presentation of
viral antigens to the immune system.
It is generally considered that env is an important protective
antigen (30) certainly in terms of priming for the production of
virus-neutralizing antibodies. This belief is to some extent con-
firmed by the success of the commercial vaccine that contains
only p45env as antigen (45). However, other viral antigens may
contribute to the generation of cell-mediated immunity. While
virus-neutralizing antibodies are important in blocking the fur-
ther spread of virus to uninfected cells and in establishing
resistance to FeLV infection (23), cell-mediated immunity is
likely to be important in the elimination of cells already in-
fected with virus during transient infection (5) and in protect-
ing against the development of latent infection. Indeed, in
studies of vaccination against murine leukemia virus, protec-
tion against challenge with tumor cells has been achieved by
immunization with gag DNA alone (6). Accordingly, we at-
tempted to potentiate a Th1-type cell-mediated immune re-
sponse by using the genes of the cytokines IFN-g, IL-12, and
IL-18 as adjuvants. Studies in vitro have demonstrated that
IL-12 and IL-18 act synergistically on T cells to produce an
increase in IFN-g production (37, 46), an extremely pleiotropic
cytokine that is integral to the development of a functional
cellular immune response (11). In vivo, the efficacy of DNA
vaccines can be augmented by the coinoculation of plasmids
expressing either IFN-g, IL-12, or IL-18 that enhance the de-
velopment of Th1 cell populations, the production of Th1
cytokines, and the generation of antigen-specific CTL re-
sponses, which are essential in the development of functional
cellular immunity (7, 25, 27, 34, 62, 63, 69). Therefore, in this
study, it is likely that the combination of IL-12 and IL-18,
which potently enhanced the protection conferred by the
FeLV DNA vaccine, mediated its adjuvant effect in vivo
through a synergistic increase in IFN-g production.
Paradoxically, the IFN-g DNA construct was not an effective
adjuvant in this trial, although plasmids expressing IFN-g have
been found to enhance other DNA vaccines (25, 54). Our
IFN-g DNA construct may have been ineffective because the
levels of IFN-g protein expressed were too low or too localized
to stimulate the immune system effectively. In contrast, as a
result of their synergistic action, the IL-12 and IL-18 DNA
constructs may have stimulated the production of enhanced
levels of IFN-g, which overcame the deficiency. An alternative
explanation is that, because IFN-g may directly inhibit the
expression of genes driven by the CMV or SV40 promoters
(21), the simultaneous administration of the plasmid express-
ing IFN-g with the vaccine DNA (which is under the control of
a CMV promoter) decreased the expression of the FeLV an-
tigens to such an extent that an effective immune response was
not elicited.
Due to logistical constraints we were unable to include in
this study a group of vaccinates given FeLV DNA and IL-18
DNA alone, which might have answered the question of
whether a single component or the combination of IL-12 and
IL-18 was responsible for enhancing the efficacy of the success-
ful vaccine. It was surprising that inoculation of vaccine and
IL-12 alone as an adjuvant appeared to reduce vaccine efficacy.
Thus, the proportion of cats that became viremic following
challenge was similar in groups C (vaccine and IL-12) and E
(control group) but was consistently greater than in group A
(vaccine alone), although the differences were not statistically
significant. The reason for the failure of the IL-12 adjuvant
alone to enhance vaccine efficacy is not known. The IL-12
construct consisted of two separate plasmids, expressing either
the p35 or the p40 subunit. Studies of human and murine IL-12
have shown that overexpression of p40 relative to p35 may
result in the generation of p40 homodimers (which behave as
receptor antagonists in vitro), inhibiting the biological activity
of endogenous IL-12 (17, 42). Similarly, inoculation with the
separate feline p35 and p40 IL-12 constructs may have resulted
in the overexpression of the p40 subunit due to differences in
transfection levels of target cells. The consequent formation of
p40 homodimers and the inhibition of the immunostimulatory
effects of endogenous IL-12 (4) may have downregulated the
cellular immune response and thus reduced the efficacy of the
vaccine. Due to the lack of feline IL-12- and IL-18-specific
bioassays, the biological activity of our expressed IL-12 and
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IL-18 proteins could not be evaluated. Therefore, it is difficult
to draw definite conclusions regarding the in vivo effects of
these cytokines. Studies are in progress to develop feline-spe-
cific bioassays that will allow the bioactivity of a particular
cytokine construct to be thoroughly assessed in vitro, before
the inoculation of animals. Future vaccine trials should include
a group with vaccine and IL-18 alone so as to determine
whether IL-18, rather than the combination of IL-12 and IL-
18, mediated the potent adjuvant effect that was observed here.
The absence of a detectable antibody response in any cat
prior to viral challenge was very striking. Although most other
FeLV vaccines do not induce significant levels of virus-neu-
tralizing antibodies (29, 31), antibodies to gp70 or other FeLV
antigens are commonly elicited (8, 55). While DNA vaccines
have been shown to induce potent cellular and humoral im-
mune responses in a variety of animal disease models (12, 47),
relatively few DNA vaccination trials have been conducted in
cats. Studies investigating the feline humoral immune response
induced by immunization with naked plasmid DNA have pro-
vided conflicting results (10, 25, 50, 60). Intramuscular DNA
vaccination with a defective FIV provirus conferred significant
protection against FIV infection in the absence of a detectable
prechallenge antiviral antibody titer (25). Similarly, inocula-
tion with a minimalistic immunogenic defined gene expression
vector (MIDGE) vaccine containing the genes coding for FIV
gp140 and feline IL-12 conferred significant protection in the
absence of a detectable virus-specific humoral immune re-
sponse (40). In contrast, intramuscular immunization with
DNA plasmids encoding the FIV gp120 protein was able to
elicit an FIV-specific humoral immune response (10).
The inability of the FeLV DNA vaccines to induce FeLV-
specific antibodies before challenge may reflect the pathway by
which the viral proteins were processed by antigen-presenting
cells. Alternatively, anti-DNA or anti-cytokine antibodies, pro-
duced as a result of immunization with plasmid DNA or in vivo
expression of cytokine adjuvant DNA constructs (48, 71), may
have interfered with the humoral immune response against the
antigenic components of the DNA vaccine (36). If such inhi-
bition did occur, it was not a permanent effect, since after
challenge high levels of virus-neutralizing antibodies appeared
in all but two of the cats that did not develop a persistent
infection. As expected, neutralizing antibodies were not found
in viremic cats, which appear to be anergic or immunotolerant
to FeLV antigens. There is no evidence from our results that
any vaccine even primed the cats for an antiviral antibody
response since the antibodies that were produced after chal-
lenge neither appeared any earlier in the vaccinates than in the
control cats that recovered naturally from infection nor
achieved higher titers. This result also indicates that the effec-
tive vaccine did not induce “sterilizing” immunity and that
there was a transient, undetected growth of the challenge virus
that induced antibody production. It is most likely that protec-
tion was achieved through the induction of cell-mediated im-
munity. The induction of FeLV-specific cytotoxic T cells fol-
lowing vaccination and before challenge could not be
investigated in this study. It may be significant, however, that
very much higher levels of effector CTL were demonstrated in
a selection of the vaccinated, protected cats than in viremic or
naturally recovered cats that were tested subsequently (14).
Certainly, the FeLV DNA and IL-12 and IL-18 adjuvant
combination was an effective vaccine, being safe to administer
and conferring a degree of protection from transient, persis-
tent, and latent FeLV infection that was at least equal to, and
in most cases superior to, that produced by other commercial
and experimental FeLV vaccines (65). Future studies should
elucidate fully the protective mechanism of the vaccine and the
cytokine adjuvants. The potential for manipulating the nature
and quantity of an immune response by cytokine gene adju-
vants might also be investigated in the use of DNA vaccines for
immunotherapy aimed at curing cats of FeLV viremia.
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